AKT1 and neoplasm: Immunoblot analysis of tumor lysates from tumors harvested at 28 days of treatment revealed greater inhibition of P-AKT and P-Erk in xenografts treated with the combination compared to xenografts treated with lapatinib alone (Figure 1C).